Stephens downgraded Avid Bioservices (CDMO) to Equal Weight from Overweight with a price target of $12.50, up from $12, after Avid filed its merger proxy associated with GHO/Ampersand’s proposed acquisition. It seems like this deal is likely to go through as proposed, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDMO: